ALX Oncology
ALX Oncology is a clinical-stage immuno-oncology company based in Burlingame, California, established in 2015. The company specializes in developing innovative therapies aimed at treating various forms of cancer, with a particular focus on its lead product candidate, ALX148. This therapeutic agent is designed to block the CD47 protein, which cancer cells exploit to evade the immune system. ALX148 is currently being investigated for its efficacy in treating myelodysplastic syndromes, acute myeloid leukemia, and several solid tumor types, including head and neck squamous cell carcinoma and certain gastric cancers. The company leverages advanced protein engineering technologies to enhance the affinity of its CD47 blockers, aiming to minimize hematologic toxicities often associated with existing treatments. ALX Oncology's commitment to improving cancer therapies is rooted in pioneering research conducted by its founders at Stanford University.
Top Regions
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
1 past transactions
ScalmiBio
Acquisition in 2021
ScalmiBio is an early-stage biotechnology company specializing in the development of innovative therapies for oncology and immuno-oncology applications. The company has created a novel technology that transforms therapeutic antibodies into pro-drugs, which are activated specifically within tumors. This targeted approach restricts the activity of the drugs to the tumor micro-environment, allowing for safer and more effective treatment options. By minimizing side effects, ScalmiBio aims to enhance the use of combination treatments and enable the administration of higher therapeutic doses, ultimately improving patient outcomes in cancer care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.